Paul M. Ridker

DEC 2016RidkerCirculation

The Pooled Cohort Equations 3 Years On

Canakinumab reduces cardiovascular events across patients with and without moderate-to-severe CKD.

This review highlights how targeting sterile, innate immunity-driven inflammation (such as the NLRP3-IL-1-IL-6 pathway) represents a promising therapeutic strategy to reduce cardiovascular risk and slow disease progression in patients with CKD.

OCT 2023RidkerCirculation

The Time to Initiate Anti-Inflammatory Therapy for Patients With Chronic Coronary Atherosclerosis Has Arrived

High heart failure polygenic risk score linked to ~5-fold higher rate of new-onset HF.

HF polygenic risk score was associated with incident heart failure; leaves open whether it improves clinical risk stratification or prevention.

A Quantitative Model to Estimate Free Il-6 Levels Among Participants Treated With the Il-6 Ligand Inhibitor Ziltivekimab: Implications for the Zeus, Hermes, and Artemis Trials

AUG 1RayAtherosclerosis

Oral Nlrp3 Inhibitor Ruvonoflast Provides Rapid, Robust and Reversible Inflammation Reduction in People With Residual Inflammatory Risk of Ascvd

Meat Intake, Metabolic Variation, and Cardiovascular Disease Risk in Women

AUG 2006AlbertCirculation

C-Reactive Protein as a Risk Predictor

APR 2006TsimikasJournal of the American College of Cardiology

hsCRP and emerging plasma biomarkers improve CVD diagnosis, risk stratification, and prognosis.

Emerging plasma biomarkers, specifically hs-CRP, have significant diagnostic and prognostic potential to improve vascular risk prediction and guide statin therapy in primary and secondary prevention of cardiovascular disease.

Anthocyanin and Blueberry Intake, Lipids, C‐Reactive Protein, and the Risk of Cardiovascular Disease in Women

Background Anthocyanins and anthocyanin‐rich berries have demonstrated lipid‐lowering and anti‐inflammatory effects; however, associations with cardiovascular disease remain mixed. We therefore examined anthocyanin and blueberry intake for prospective associations with cardiovascular disease risk and cross‐sectional associations with lipids and hs‐CRP (high‐sensitivity C‐reactive protein) in the WHS (Women's Health Study). Methods Among 38 088 women who completed a baseline semiquantitative food frequency questionnaire in 1992 to 1995, we estimated intake of total anthocyanins, 6 anthocyanin subclasses, and blueberries. Multivariable hazard ratios (HRs) were calculated for confirmed major adverse cardiovascular events, including nonfatal myocardial infarction, nonfatal stroke, and cardiovascular disease death. In a subset of 26 912 women with baseline blood samples, multivariable odds ratios were calculated for adverse lipid and hs‐CRP levels. Results During a median 28.0‐year follow‐up, 2752 major adverse cardiovascular event cases occurred. Age‐, energy‐, and WHS treatment–adjusted HRs across quintiles of total anthocyanin intake were 1.00 (reference), 0.87 (95% CI, 0.78–0.98), 0.79 (95% CI, 0.70–0.89), 0.81 (95% CI, 0.72–0.91), and 0.88 (95% CI, 0.79–0.99) ( P ‐trend=0.23). Further adjustment for clinical, lifestyle, and dietary factors showed no significant associations with major adverse cardiovascular events or their components, with similar null findings observed for anthocyanin subclasses and blueberries. In cross‐sectional analyses, higher total anthocyanins and anthocyanin subclasses, except pelargonidin, were significantly associated with lower multivariable‐adjusted odds of adverse high‐density lipoprotein cholesterol and triglycerides (all other P ‐trend<0.05). Conclusions In the WHS, anthocyanin and blueberry intake were not significantly associated with cardiovascular disease risk. However, higher anthocyanin intake was cross‐sectionally associated with lower odds of adverse high‐density lipoprotein cholesterol and triglycerides.

Universal screening for high-sensitivity C-reactive protein in patients with atherosclerotic disease represents a major therapeutic opportunity.

The authors discuss the therapeutic opportunity of universal screening for hsCRP in patients with atherosclerotic disease.

Early screening for LDL cholesterol, hsCRP, and Lipoprotein(a) enhances long-term cardiovascular risk prediction in primary prevention, despite methodological critiques regarding estimation methods.

Early measurement of biomarkers including LDL cholesterol, hsCRP, and Lp(a) can enhance cardiovascular risk prediction and motivate early lifestyle interventions in primary prevention.